North America, which includes the United States and Canada, is Novo Nordisk’s (NVO) largest market. It accounts for about 48% of the company’s total sales.
Novo Nordisk has developed certain core capabilities that differentiate the company from its competition. One is establishing local organizations in emerging markets and then growing organically.
Novo Nordisk’s (NVO) growth hormone therapy Norditropin is currently a market leader in the growth disorders segment. It’s estimated that 2 million people qualify for growth hormone therapy.
Novo Nordisk is pursuing leadership in the hemophilia market with its new drugs as well as a few investigational hemophilia drugs in its late-stage research pipeline.
According to projections by Novo Nordisk (NVO), targeting the obesity market by pharmaceutical companies is about 4–5 DKK (Danish krone currency) in value.
With 71% market share, Victoza is currently the market leader in the GLP-1 segment. GLP-1 therapy accounts for 8.5% of the total diabetes market in the United States.
Novo Nordisk’s human insulin revenues have gradually declined from 2012 to 2014. This is mainly due to the loss of a large tender contract, which resulted in fewer patients treated by human insulin.
Novo Nordisk (NVO) holds a dominant position in insulin therapy, with 46% market share in the global modern insulin and next-generation insulin market.
Novo Nordisk’s (NVO) modern insulin portfolio is a major growth revenue driver. The company markets modern insulin drugs Levemir, NovoRapid, and NovoMix in North America, Europe, and Asia.
Novo Nordisk’s (NVO) business model includes a portfolio in areas such as diabetes, hemophilia, and growth hormones. In the first half of 2015, diabetes care accounted for 78.6% of its total revenues.
Novo Nordisk (NVO) is a leader in diabetes care with 90 years of experience coupled with a strong workforce of 39,700 in 75 countries around the world.
Cantel Medical outperformed its peers based on the net profit margin, current ratio, PE ratio, and PBV ratio. It outperformed its ETFs based on the PBV ratio.
Cantel Medical reported net revenue of $151.255 million in 4Q15—a rise of 6.88% compared to the net revenue of $141.508 million in 3Q15.
BioMarin Pharmaceutical (BMRN) has a market cap of $16 billion. BMRN fell 16.81% last week and closed at $108.69. That’s below the 20-day, 50-day, and 100-day moving averages.
In the small-cap space, the top ten stocks of XBI had an average return of -12.18% for the week ended September 25, 2015. This is similar to XBI’s top ten large-cap stocks that returned -12.15%.
Alnylam Pharmaceuticals (ALNY) dragged down mid-cap stocks for the week ended September 25. ALNY fell 22.37%, closing at $83.72. It was trading below the 20-day, 50-day, and 100-day moving averages.
BioMarin Pharmaceutical (BMRN) fell 16.81% and closed at $108.69 last week. That’s below the 20-day, 50-day, and 100-day moving averages. The 14-day RSI was 28, or oversold territory.
XBI’s moving average took a hit in the week ended September 25, and most of its stocks were trading below all the moving averages. Compared to the previous week, the fall was massive.
Last week was an unforgettable week for biotech stocks. It began on a bad note after Hillary Clinton commented on price controls for the specialty drug market, which created panic and triggered a sell-off.
The top five small-cap stocks from the pharmaceutical subgroup of the iShares Nasdaq Biotechnology ETF (IBB) outperformed the IBB and the broader market SPDR S&P 500 ETF.